Autifony to speak at the Schizophrenia International Research Society (SIRS) meeting in Florence 6 – 10th April
Stevenage, 21st March 2022 – Autifony CEO Charles Large will be speaking in the Pharmaceutical Pipeline session at this year’s SIRS conference in Florence, Italy. Dr Large will present new analysis of the effects of Autifony’s lead Kv3 modulator, AUT00206 on gamma electroencephalographic activity, a key biomarker for efficacy in patients with schizophrenia.
Autifony – SIRS Pharma Pipeline April 2022 (3.53 MB)
SIRS 2022 Poster (3.06 MB)